Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

10.5%

2 terminated out of 19 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results60% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (2)
P 1 (5)
P 2 (5)
P 3 (1)

Trial Status

Active Not Recruiting6
Recruiting4
Unknown4
Completed3
Terminated2

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT04713618Active Not RecruitingPrimary

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

NCT07407647Phase 2RecruitingPrimary

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT00867464Active Not RecruitingPrimary

Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

NCT04505553Phase 2Completed

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

NCT02408861Phase 1Terminated

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT04272034Phase 1Terminated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

NCT02628067Phase 2Active Not Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

NCT07118176Phase 1RecruitingPrimary

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT02816879Not ApplicableActive Not RecruitingPrimary

Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men

NCT05663502RecruitingPrimary

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

NCT04802876Phase 2Active Not Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

NCT04230759Phase 2Active Not Recruiting

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

NCT05787535Phase 1Unknown

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

NCT05438836Recruiting

Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

NCT03469596CompletedPrimary

Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor?

NCT02369939Phase 3UnknownPrimary

Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy

NCT03241680Not ApplicableUnknownPrimary

Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III)

NCT01877135Unknown

Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients

NCT00423254Phase 1Completed

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Showing all 19 trials

Research Network

Activity Timeline